Udvalget for Humanmedicinske Lægemidler (CHMP) konkluderede, at fordelene ved Protaphane er større end risiciene ved behandling af diabetes.
The Committee for Medicinal products for Human Use (CHMP) decided that Protaphane’ s benefits are greater than its risks for the treatment of diabetes.